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INTRODUCTION
Lung cancer is the most prevalent and lethal cancer world-
wide, and has been reported in many nations, including the
Republic of Korea and many Western countries (1). The high
mortality rate attributed to lung cancer may be the result of
induced multi-drug resistance and a high frequency of me-
tastatic occurrence. Despite aggressive treatment with sur-
gery, radiation, and chemotherapy, survival rates for lung
cancer patients remain low (2). New approaches to the treat-
ment of lung cancer are urgently needed. Immunotherapy
may represent one such approach, and several different strate-
gies for lung cancer immunotherapy have recently been de-
veloped (3). 
The goal of cancer immunotherapy is to augment the weak-
ened host immune response against tumors using specific
and/or nonspecific immune stimulants. Treatment may in-
clude the administration of cytokines, tumor-specific anti-
bodies, and T-cells (3-5). Toxoplasma gondii is an obligate intra-
cellular parasite; latent infections with T. gondii are common
in human populations throughout the world (6). It has been
reported that the development of spontaneous mammary
tumors, leukemia, and 20-methylcholanthrene-autoinduced
tumors is suppressed in animal models following injection
of Toxoplasma antigen or viable parasites (7, 8). Both Toxo-
plasma infection and the cell-free parasite extract are able to
reverse the multi-drug resistance of mouse lymphoma and
human gastric cancers in vitro (9). Moreover, potent antitu-
mor effects are induced by intralesional injection with for-
malin-fixed T. gondii organisms in Lewis lung carcinoma
(LLC) in Toxoplasma-infected mice (10, 11).
These reports suggest that T. gondii is a powerful agent for
cancer immunotherapy, and is useful as a stimulant of the
cellular immune responses. Recently, there were many reports
that antitumor and antimetastatic actions are associated with
inhibition of tumor-induced neovascularization (12-14). How-
ever, the immunologic mechanisms of the antitumor activi-
ty elicited by T. gondii in lung cancer, as well as the immu-
nological characteristics of LLC, are not well documented.
Also, the anti-angiogenic effects of T. gondii have not been
determined in the LLC mouse model. In order to determine
the antitumor and anti-angiogenic activities of T. gondii in-
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Inhibition of Lewis Lung Carcinoma Growth by Toxoplasma gondii
through Induction of Th1 Immune Responses and Inhibition of 
Angiogenesis 
Toxoplasma gondii is an obligate intracellular protozoan parasite that induces anti-
tumor activity against certain types of cancers. However, little information is avail-
able regarding the immunologic mechanisms that regulate these effects. For this
purpose, C57BL/6 mice were administered either the T. gondii Me49 strain orally
or Lewis lung carcinoma (LLC) cells intramuscularly. Survival rates, tumor size,
histopathology, and immune responses were determined for each group, and angio-
genesis was evaluated by in vivo Matrigel plug assay. Toxoplasma-infected (TG-
injected) mice survived the entire experimental period, whereas cancer cell-bear-
ing (LLC-injected) mice died within six weeks. Mice injected with both T. gondii and
cancer cells (TG/LLC-injected group) showed significantly increased survival rates,
CD8
+ T-cell percentages, IFN- mRNA expression levels, serum IgG2a titers, and
CTL responses as compared to the LLC-injected mice. In addition, angiogenesis
in the TG/LLC-injected mice was notably inhibited. These effects in TG/LCC-injected
mice were similar or were increased by the addition of an adjuvant, Quil-A. How-
ever, TG/LLC-injected mice showed decreased percentages of CD4
+ and CD8
+ T-
cells, IFN- mRNA expression levels, and serum IgG1 and IgG2a titers as com-
pared to TG-injected mice. Taken together, our results demonstrate that T. gondii
infection inhibits tumor growth in the Lewis lung carcinoma mouse model through
the induction of Th1 immune responses and antiangiogenic activity.
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fection in LLC-bearing mice, C57BL/6 mice were injected
with LLC cells alone or in combination with T. gondii. And
then, we evaluated the survival rates, tumor size, histopathol-
ogy, cell-mediated immune responses, and angiogenesis.
MATERIALS AND METHODS
Mice and parasite strains
Female inbred C57BL/6 mice were obtained from the
Korea Research Institute of Bioscience and Biotechnology,
Daejeon, Korea. All mice used were 6-8 weeks old and doc-
umented as specific pathogen-free animals. All animal stud-
ies were carried out in a pathogen-free barrier zone at the
College of Medicine, Chungnam National University, in
accordance with the procedures outlined in the Guide for
the Care and Use of Laboratory Animals. Two strains of T.
gondii were used; the RH strain was used to prepare Toxo-
plasma lysate antigen (TLA) and mice were orally infected
with the Me49 strain to evaluate antitumor activity. 
Lewis lung carcinoma (LLC) cell cultures and experimen-
tal groups
The LLC cell line was obtained from the American Type
Culture Collection (ATCC, Rockville, MD, U.S.A.) and was
cultured in a humidified atmosphere of 5% CO2 at 37℃
using Dulbecco’s modified Eagle’s medium (DMEM) (Gib-
coBRL Co., Grand Island, NY, U.S.A.) that contained 10%
heat-inactivated fetal bovine serum (FBS; GibcoBRL), 2 mM
glutamine, 100 U/mL penicillin, and 100  g/mL strepto-
mycin.
Mice were divided into seven experimental groups. Each
group was composed of 50 mice; 10 mice to evaluate survi-
val rates, 35 mice to evaluate immunologic characteristics,
and 5 mice to check angiogenesis. The seven experimental
groups included mice that were administered with: LLC cells
(LLC-injected group); T. gondii (TG-injected group); both
Toxoplasma parasites and LLC cells (TG/LLC-injected group);
Quil-A only (QA-injected group) (Accurate Chemical and
Scientific Co., Westbury, NY, U.S.A.); both LLC cells and
Quil-A (LLC/QA-injected group); both T. gondii and Quil-A
(TG/QA-injected group); and T. gondii, LLC cells and Quil-
A (TG/LLC/QA-injected group). To calculate the survival
rate for each group, the mice were examined each day for
eight weeks following LLC cell injection or T. gondii infec-
tion. To evaluate the immunological mechanisms of antitu-
mor activity induced by Toxoplasma, mice were sacrificed
weekly and blood, muscle, lung, and spleen tissues were col-
lected. In addition, we checked the antiangiogenic activity
and cytotoxic T-lymphocyte responses one week after infec-
tion with T. gondii. Untreated age- and sex-matched control
mice were treated with equivalent doses of normal saline. 
In vivo evaluation of antitumor activity
According to the experimental protocol, mice were inject-
ed with LLC cells, T. gondii parasites or Quil-A. LLC cells
were implanted at a density of 1×105 viable cells into the
femoral muscle and Quil-A (20  g per mouse) was injected
intraperitoneally twice weekly for three consecutive weeks.
Mice were orally infected with five cysts of the T. gondii Me49
strain. The extent of tumor growth was measured weekly
using sterile metric calipers. Tumor volume was calculated
using the following formula (13): tumor volume ( L)=tumor
width (mm)2×tumor length (mm)×0.5.
Histopathological analysis 
The lung and muscle samples from each mouse were re-
moved immediately after anesthesia and placed in 10% bu-
ffered neutral formaldehyde (Polyscience Inc., Warrington,
PA, U.S.A.). Paraffin-embedded tissues were cut and stained
with hematoxylin and eosin (H-E), and the cancer cells were
examined using a bright-field microscope.
Enzyme-linked immunosorbent assay (ELISA)
Serum samples were obtained from each mouse, and the
IgG subclasses were quantified. TLA was prepared accord-
ing to the protocol outlined by Lee et al. (15). Each well of a
96-well plate was coated with TLA (10  g/mL) and incubat-
ed overnight at 4℃. After blocking, serum samples were
diluted 1:100 in 0.1% bovine serum albumin/phosphate-
buffered saline (BSA/PBS) that contained 0.05% Tween-20,
and 100  L of sample was added to each well. The plates were
incubated for 2 hr, and HRP-conjugated goat anti-mouse
IgG1 or IgG2a (Southern Biotechnology Associates Inc., Birm-
ingham, AL, U.S.A.) was added. Following the final wash-
ing step, freshly prepared O-phenylenediamine dihydrochlo-
ride was added, and the reaction was stopped by the addition
of 4 N H2SO4. The optical density was read at 492 nm using
an automated ELISA reader (Tecan A-5082, Salzburg, Austria).
Splenocyte preparation and flow cytometry
Following removal, the spleens were homogenized and
erythrocytes were lysed in Tris-NH4Cl (pH 7.2). Splenocyte
extracts that contained 1×106 cells were incubated with 50
L of fluorescein isothiocyanate (FITC)-conjugated anti-mou-
se CD4
+ and CD8
+ monoclonal antibodies or an isotype-spe-
cific control (1:100 dilution in 0.1% BSA/PBS; PharMin-
gen, San Diego, CA, U.S.A.) for 1 hr at 4℃. The cells were
washed three times in 0.1% BSA/PBS with centrifugation,
and then fixed with 1% paraformaldehyde and analyzed by
flow cytometry (FACScan; Becton Dickinson, Franklin Lakes,
NJ, U.S.A.). All data were analyzed using the Cell-Quest
program (Becton Dickinson).S40 J.-O. Kim, S.-S. Jung, S.-Y. Kim, et al.
RT-PCR assessment of cytokines
Splenic cytokine mRNA expression was assessed accord-
ing to the methods of Lee et al. (15). Each sample was pro-
cessed for total mRNA isolation using the RNAgent kit
(Promega, Madison, WI, U.S.A.). The cDNA was prepared
using a starting mixture that contained 5  g of total RNA,
8  L of 5×RT buffer, 4  L of dNTPs, 25  M oligo (dT),
and 1  L of avian myeloblastosis virus (AMV) reverse tran-
scriptase. PCR was performed using 2-13  L of the cDNA
reaction mixture that contained 10×polymerase buffer, 250
M dNTPs, 0.4  M of the 3′ -primer and 5′ -primer, and 2.5
U Taq polymerase. Each PCR cycle consisted of 94℃ for 1
min, 57℃ for 1 min, and 72℃ for 1 min. The cytokine
primer sequences were as follows: for hypoxanthine phospo-
ribosyltransferase (HPRT), 3′ -GAGGGTAGGCTGGCCT-
ATGGCT-5′ and 5′ -TTGGATACAGGCCAGACTTTGT-
TG-3′ ; for interferon gamma (IFN- ), 3′ -CTCATGGAAT-
GCATCCTTTTTCG-5′ and 5′ -ACGCTACACAC-TGCA-
TCTTGG-3′ ; and for interleukin-10 (IL-10), 3′ -TGTCTA-
GGTCCTGGAGTCCAGCAGACTCAA-5′ and 5′ -CCA-
GTTTTACCTGGTAGAAGTGATG-3′ . After 35 PCR
cycles, the products were separated by electrophoresis on 2%
agarose gels. Quantification of mRNA was performed with
an imaging densitometer (Bio-Rad, Hercules, CA, U.S.A.).
Cytotoxic T lymphocyte assay 
One week after T. gondii (or cancer cell) injection, splenic
lymphocytes were isolated from each group and cultured in
RPMI 1640 for three days. The splenocytes were then co-cul-
tured with irradiated LLC cells at various effector to target
(E:T) ratios for seven days. One  Ci of 51Cr (NEN Research
Products, Boston, MA, U.S.A.) was added to each well and
the plate was allowed to incubate for 3 hr. The plate was then
washed several times with RPMI 1640 until the culture
supernatant contained <500 counts per minute (CPM) of
51Cr. The plates were incubated for an additional 4 hr at 37℃,
followed by removal of 100  L of each sample, and the CPM
were determined by a gamma counter (Beckman, Fullerton,
CA, U.S.A.). The percent lysis was calculated as follows: per-
cent lysis=(mean CPM of test sample-mean CPM of sponta-
neous release)/(mean CPM of maximal release-mean CPM
of spontaneous release)×100.
Matrigel angiogenesis assay
Matrigel angiogenesis assay was performed as described
by Passaniti et al. (16). One week after T. gondii (or cancer
cell) injection, the C57BL/6 mice were injected subcutaneous-
ly near the abdominal mid-line using a 25G needle with 0.5
mL Matrigel (BD Bioscience, Bedford, MA, U.S.A.) that
contained 300 ng of basic fibroblast growth factor (bFGF;
Sigma Chemical Co., St. Louis, MO, U.S.A.) and 32 U/mL
heparin (Sigma). The injected Matrigel rapidly formed a sin-
gle, solid gel and the mice were sacrificed six days later. The
underlying skin of the mouse was removed, and the gels were
recovered for hemoglobin (Hb) measurement using the Drab-
kin reagent kit (Sigma). Hemoglobin concentrations were
calculated from a known Hb control, which was run in par-
allel. 
Statistical analysis
All results are expressed as the mean±standard error (SE)
for each group. Kaplan-Meier and Log-Rank tests were per-
formed to analyze the differences in survival rates. To evalu-
ate differences in tumor sizes, antibody titers, phenotype
profiles, cytokine mRNA levels, Hb concentrations, and
cytotoxicity, Kruskal-Wallis tests were used to check for sta-
tistical differences among the groups. Differences between
groups were considered significant at p<0.05.
RESULTS
Increased survival rates of cancer-bearing mice by 
T. gondii infection
Mice were treated with T. gondii parasites, LLC cells, or
Quil-A according to our protocol, and survival rates were
evaluated over eight weeks. As shown in Fig. 1, the TG-,
QA-, and TG/QA-injected mice survived the entire experi-
mental period. However, the LLC- and LLC/QA-injected
mice began dying 28 days after cancer cell injection, and all
of these mice died after 39 days. The survival rate of the TG/
LLC-injected mice was 20%, and the TG/LLC/QA-injected
mice had a 30% survival rate at 8 weeks after cancer cell
injection, which were significantly higher than the rates for
the LLC- and LLC/QA-injected mice (p<0.05).
T. gondii infection inhibits the tumor growth in mice 
Mice infected with T. gondii developed brain cysts within
two weeks of infection (data not shown). Cancer cells were
observed in the muscle tissues within one week in the LLC-
and LLC/QA-injected groups (Fig. 2A, B). However, cancer
cells were found in the TG/LLC- and TG/LLC/QA-injected
mice by two weeks. In addition, cancer cells were found in the
lungs three weeks after LLC cell injection in the LLC- and
LLC/QA-injected groups (Fig. 2C, D), whereas cancer they
were found within five weeks in TG/LLC- and TG/LLC/QA-
injected mice. The skin overlying the tumor began to ulcerate
three to four weeks after cancer cell injection in the LLC-inject-
ed mice (Fig. 2E), whereas ulceration was observed within
five weeks in the TG/LLC- and TG/LLC/QA-injected mice.
Tumor masses were palpable by two to three weeks after
cancer cell injection in the cancer-bearing LLC-, LLC/QA-,Antitumor and Antiangiogenesis by T. gondii   S41
TG/LLC-, and TG/LLC/QA-injected mice. In the LLC- and
LLC/QA-injected mice, tumor masses increased abruptly in
size at two to four weeks after cancer cell injection, and the
tumor volumes at four weeks were 8,760±465 and 6,740
±360  L, respectively (Fig. 3). The tumor volumes were
significantly decreased in the TG/LLC- and TG/LLC/QA-
injected mice (2,155±520  L and 1,980±342 L,  respec-
tively) at four weeks as compared with the LLC- and LLC/
QA-injected mice (p<0.05). 
IgG2a titers were increased in T. gondii-infected cancer-
bearing mice
Serum samples were assayed for IgG subclasses against
TLA by ELISA. The specific IgG1 and IgG2a titers of the
LLC-, QA-, and LLC/QA-injected mice were similar to those
of control mice. However, the specific IgG1 titers of the TG-
and TG/QA-injected mice were significantly increased after
one week of T. gondii infection (Fig. 4A). In addition, the
IgG1 titers of the TG/LLC- and TG/LLC/QA-injected mice
were markedly depressed following cancer cell injection as
compared with the TG- and TG/QA-injected mice (p<0.05). 
The IgG2a titers of the TG- and TG/QA-injected mice
were significantly increased after T. gondii infection as com-
pared to the control mice. In the TG/LLC- and TG/LLC/QA-
injected mice, the IgG2a titers following cancer cell injec-
tion were significantly depressed until four weeks compared
with those of the TG- and TG/QA-injected mice, although
the IgG2a titers increased abruptly thereafter (Fig. 4B). 
Fig. 2. Histopathologic findings for the muscles and lungs of C57-
BL/6 mice injected with T. gondii, LLC cells or Quil-A. Paraffin-
embedded tissues were stained with hematoxylin and eosin, and
visualized under a microscope at ×400 magnification. (A) Nor-
mal muscle; (B) cancerous changes in the muscle at cancer cell-
injected sites; (C) normal lung; (D) cancerous changes in the lung
(cancer metastasis to the lungs); (E) tumor masses of mice in-
jected with LLC cells (left and middle) and injected with both T.
gondii and LLC cells (right). Ulceration was observed in cancer-
bearing mice (arrow).
A B
C D
E
Fig. 1. Survival rates of C57BL/6 mice injected with Toxoplasma
gondii, Lewis lung carcinoma (LLC) cells or Quil-A. Mice were
checked daily for eight weeks following cancer cell injection, to
measure survival rates. The groups (n=10 per group) were as fol-
lows: LLC, injected in the femoral muscle with 1×10
5 viable LLC
cells; TG, infected with five cysts of the Me49 strain of T. gondii;
TG/LLC, received both Toxoplasma parasites and LLC cells; QA,
received 20  g/mouse of Quil-A twice weekly for 3 weeks; LLC/
QA, received both LLC cells and Quil-A; TG/QA, received both T.
gondii and Quil-A; TG/LLC/QA, received T. gondii, LLC cells, and
Quil-A.
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Fig. 3. Sizes of tumors in C57BL/6 mice injected with T. gondii,
LLC cells or Quil-A. Tumor growth was measured weekly using
sterile metric calipers. Tumor volume ( L)=tumor width (mm)
2×
tumor length (mm)×0.5. Data are presented as the means±SE
of five mice (*, p<0.05 compared with LLC- or LLC/QA-injected
group).
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CD4
+ and CD8
+ T-cells are decreased in cancer-bearing
mice
To evaluate changes in T-cell subtypes following either T.
gondii infection or cancer cell injection, we analyzed the phe-
notypic profiles of murine splenocytes. The percentages of
CD4
+ T-cells in the TG-injected mice were temporarily dec-
reased at one to two weeks post-infection compared to those
of the control mice, and these levels returned to baseline shortly
thereafter (Table 1). The percentages of CD4
+ T-cells in the
LLC-, LLC/QA-, TG/LLC-, and TG/LLC/QA-injected mice
were significantly decreased following cancer cell injection
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Fig. 4. Serum IgG1 (A) and IgG2a (B) titers of C57BL/6 mice injected with T. gondii, LLC cells or Quil-A, as measured by ELISA. Serum
samples were obtained from mice at the indicated time-points, and the IgG subclasses against Toxoplasma lysate antigen were quanti-
fied. Data are presented as the mean±SE of five mice (*, p<0.05 compared with LLC- or LLC/QA-injected group; 
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with TG- or TG/QA-injected group). 
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LLC 28.0±1.8 24.7±1.4 26.0±1.6 19.0±0.8* 16.0±1.6* - -
TG 28.0±1.8 25.3±0.8 23.7±1.1* 24.9±1.3 25.0±1.6 28.0±1.6 27.0±1.7
TG/LLC 28.0±1.8 23.1±1.4 24.0±2.1 15.0±1.1* 16.5±0.8* 14.2±1.3* 13.8±0.8*
QA 28.0±1.8 26.3±1.3 28.7±1.4 27.1±1.2 28.2±1.9 27.6±1.1 28.5±1.4
LLC/QA 28.0±1.8 24.7±1.8 25.1±1.9 21.0±1.3* 18.0±1.4* 17.6±1.4* -
TG/QA 28.0±1.8 23.8±1.3 24.7±1.6 27.1±1.3 26.3±1.5 28.1±1.6 29.3±1.3
TG/LLC/QA 28.0±1.8 26.3±1.3 28.0±1.7 19.6±1.2* 18.1±1.3* 15.9±0.9* 16.0±1.2*
Table 1. Percentages of CD4
+ T cell subsets in splenocytes from mice injected with T. gondii, Lewis lung carcinoma cells, or Quil-A
Splenocytes were stained with FITC-conjugated CD4 monoclonal antibody, and then analyzed by FACScan.
*Statistically significant differences compared with the control group (day 0) (p<0.05). The data are represented as the mean±SE of 5 mice.
LLC, Lewis lung carcinama; TG, T. gondii; QA, Quil-A.
Group
Weeks after T. gondii and/or cancer cells injection
012 3456
LLC 19.0±1.5 19.2±1.3 17.0±1.2 14.8±0.8* 13.2±1.5* - -
TG 19.0±1.5 17.6±1.2 16.5±0.8 18.0±1.3 22.1±1.5 19.6±1.8 20.8±1.9
TG/LLC 19.0±1.5 19.3±1.0 18.1±1.0 14.0±1.4* 12.0±0.5* 16.2±1.2* 16.5±1.1
QA 19.0±1.5 20.4±0.9 21.7±1.1 22.6±1.7 22.1±1.3 22.8±0.7 22.1±1.4
LLC/QA 19.0±1.5 17.8±1.3 16.5±1.4 15.5±1.0* 14.9±0.8 15.3±1.5* -
TG/QA 19.0±1.5 19.3±1.6 17.3±1.6 20.1±1.3 21.6±1.6 20.9±1.2 21.1±1.6
TG/LLC/QA 19.0±1.5 21.5±1.7 18.8±1.3 15.4±1.3* 14.0±1.7* 16.9±1.3 16.8±1.2
Table 2. Percentages of CD8
+ T cell subsets in splenocytes from mice injected with T. gondii, Lewis lung carcinoma cells, or Quil-A
Splenocytes were stained with FITC-conjugated CD8 monoclonal antibody, and then analyzed by FACScan. 
*Statistically significant differences compared with the control group (day 0) (p<0.05). The data are represented as the mean±SE of 5 mice.
LLC, Lewis lung carcinama; TG, T. gondii; QA, Quil-A.Antitumor and Antiangiogenesis by T. gondii   S43
and remained markedly depressed after three weeks (p<0.05).
As shown in Table 2, the percentages of CD8
+ T-cells in
the LLC-, LLC/QA-, TG/LLC-, and TG/LLC/QA-injected
mice were significantly decreased three weeks after cancer
cell injection. The LLC- and LLC/QA-injected mice main-
tained these low values, whereas the percentage of CD8
+ T-
cells in the TG/LLC- and TG/LLC/QA-injected mice recov-
ered slightly at five weeks after T. gondii infection. 
IFN- mRNA expression was significantly increased in 
T. gondii-infected cancer-bearing mice 
As shown in Fig. 5A, the levels of IFN- mRNA expres-
sion in the LLC- and LLC/QA-injected mice were increased
two- to three-fold at three weeks after cancer cell injection
as compared to the control (p<0.05). However, the levels of
IFN- mRNA expression in the TG-, TG/QA-, and TG/
LLC/QA-injected mice were increased immediately after T.
gondii infection, peaked two to three weeks post-infection
(14-19-fold increase), and slowly decreased thereafter. How-
ever, IFN- mRNA expression in the TG/LLC-injected mice
was significantly lower than that in the TG-, TG/QA-, and
TG/LLC/QA-injected mice, even though IFN- mRNA
expression in the TG/LLC-injected mice was significantly
increased by one week post-infection.  
As compared to the control mice, the levels of IL-10 mRNA
expression in the LLC- and LLC/QA-injected mice increased
significantly, by 1.3-2.3-fold, three weeks after cancer cell
injection. The levels of IL-10 mRNA expression in the TG-,
TG/QA-, and TG/LLC-injected mice increased immediately
following T. gondii infection, peaking at three weeks post-in-
fection (5.5-7.5-fold increase). However, IL-10 mRNA ex-
pression in the TG/LLC/QA-injected mice, which was signif-
icantly lower than in the TG-, TG/QA-, and TG/LLC-inject-
ed mice from 3 weeks postinfection, peaked at two weeks
and subsequently decreased.
T. gondii infection induced tumor cytolysis by splenocytes
An in vitro CTL assay was performed to determine whether
the splenic T-cells of Toxoplasma-infected cancer-bearing mice
increased cytotoxic activity against LLC cells. As shown in
Fig. 6, the LLC-, QA-, and LLC/QA-injected mice did not
show CTL responses. However, the splenocyte CTL activi-
ties of the TG- and TG/QA-injected mice increased as the
E:T ratio increased. The percentages of specific lysis seen in
the TG/LLC- and TG/LLC/QA-injected mice were consid-
erably higher than those in the LLC- and LLC/QA-injected
mice. However, the CTL activities of the TG/LLC- and TG/
LLC/QA-injected mice were significantly lower than those
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Fig. 5. Relative IFN- (A) and IL-10 (B) mRNA expression in splenocytes from C57BL/6 mice injected with T. gondii, LLC cells or Quil-A.
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Fig. 6. Cytotoxic T-cell responses of C57BL/6 mice injected with
T. gondii, LLC cells or Quil-A. One week after T. gondii (or cancer
cell) injection, splenic lymphocytes were isolated from each mou-
se, labeled with 
51Cr, and cultured with irradiated LLC cells at dif-
ferent cell ratios. Data are presented as mean±SE of five mice.
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of the TG- and TG/QA-injected mice (p<0.05).
T. gondii infection inhibits tumor angiogenesis in vivo 
The Matrigel plugs that formed following subcutaneous
implantation of Matrigel alone produced little or no local
reaction, nor did they produce an angiogenic response. How-
ever, the plugs that formed following the implantation of
Matrigel that was supplemented with bFGF and heparin
caused an angiogenic reaction (Fig. 7). We measured the Hb
concentrations inside the Matrigel plugs in order to quanti-
fy the extent of angiogenesis. The Hb concentrations in the
LLC-, QA-, and LLC/QA-injected mice ranged from 14.6±
2.0 to 16.2±1.6 g/dL, whereas those in the TG- and TG/
QA-injected mice ranged from 4.1±0.7 to 4.3±0.9 g/dL.
The Hb concentrations in the TG/LLC- and TG/LLC/QA-
injected mice were significantly lower than those in the LLC-
or LLC/QA-injected mice (p<0.05), but were not significantly
different from those in the TG- or TG/QA-injected mice. 
DISCUSSION
Tumors frequently interfere with the development and
function of immune responses (3-5). The ability of various
infections to suppress neoplastic growth has been well docu-
mented. In addition, T. gondii is a nonspecific immune stim-
ulant used for cancer immunotherapy (7-11). In the present
study, we examined the mechanisms of the antitumor effects
of T. gondii infection on lung cancer in vivo. Toxoplasma in-
fection of LLC-bearing mice significantly increased the sur-
vival rates, serum IgG2a titers, IFN- mRNA expression,
CD8
+ T-cell percentages, CTL responses, and also inhibited
angiogenesis. These values were similar or further improved
by the addition of an adjuvant, Quil-A. These results indi-
cate that T. gondii activates Th1 immune responses and inhi-
bits angiogenesis in LLC-bearing mice, leading to the induc-
tion of antitumor and antimetastatic activities. 
Cancer immunotherapy attempts to harness the exquisite
power and specificity of the immune system for the treat-
ment of malignancy. Although cancer cells are less immuno-
genic than pathogens, the immune system is clearly capable
of recognizing and eliminating tumor cells. Lung cancer
immunotherapy may represent one new approach that has
low toxicity and high specificity, but implementation has
been a challenge due to poor antigenic characterization and
the ability of lung cancers to escape immune responses (3-5,
17). Several different immunotherapeutic treatment strate-
gies and mouse models have been developed. In this study,
we utilized LLC cells, which remain highly tumorigenic in
C57BL/6 mice and produce primary tumors and lung meta-
stases histologically indistinguishable from the original tumor
line (18). In the LLC- and LLC/QA-injected mice, tumor
masses were initially palpable in the muscle tissues located
at the site of cancer cell injection from two weeks after can-
cer cell injection, and cancer cells were found in the lungs
three weeks after LLC cell injection. Thus, it was confirmed
that the LLC cell line is useful for studying the mechanisms
of cancer chemotherapeutic agents. After T. gondii infection,
tumor volumes were significantly decreased in the TG/LLC-
and TG/LLC/QA-injected mice as compared with the LLC-
and LLC/QA-injected mice. However, the mechanisms of
antitumor activity induced by T. gondii infection are not easi-
ly introduced in LLC, so we suggested the mechanisms of
antitumor effects in this study.
Infection with T. gondii results in a strong cell-mediated
immune response, especially the T-cell-mediated response
(19). In the present study, the percentages of CD8
+and CD4
+
T-cells were significantly decreased in cancer-bearing LLC-
and LLC/QA-injected mice. Following infection with T.
gondii, the percentages of CD8
+ T-cells in TG/LLC- or TG/
LLC/QA-injected mice were increased from 5 weeks post-
infection, but those of CD4
+ T-cells were not. Collectively,
these data indicate that T-cell-mediated immune responses
were severely suppressed in Lewis lung carcinoma, and T.
gondii alone or in combination with Quil-A may provide an
appropriate epitope for MHC-1 presentation (17, 19), and
therefore, the percentages of CD8
+ T-cells were recovered.
Fig. 7. Angiogenesis in C57BL/6 mice injected with T. gondii, LLC
cells or Quil-A. One week after T. gondii (or cancer cell) injection,
a Matrigel that was supplemented with heparin and basic fibrob-
last growth factor was injected into the mice. The gels were recov-
ered on day 6 postinjection for hemoglobin measurement using
the Drabkin reagent kit. Data are presented as the mean±SE of
five mice. (A) Hemoglobin content of each group; (B) Matrigel
plugs were removed 6 days after injection and photographed
(arrows): LLC-bearing mice (left), Toxoplasma-infected mice (mid-
dle), and Matrigel alone (right).
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This phenomenon is confirmed by the results of a cytotoxic
T lymphocyte assay. Namely, Toxoplasma-infected TG/LLC-
and TG/LLC/QA-injected mice demonstrated higher CTL
responses of CD8
+ T-cells than the cancer-bearing LLC- or
LLC/QA-injected mice. Previous studies have also demon-
strated that strong antitumor responses are induced by either
abundant infiltration of both CD4
+ and CD8
+ T-cells and
tumor-specific CTLs in LLC-bearing mice after treatment
with IL-2 and IL-12 (17) or increases in the numbers of apop-
totic tumor cells, CD8
+ T-cells, and natural killer (NK) cells
that invade the tumors after injection with ergosterol (14).
Cytokines serve as critical regulators of cell-mediated im-
munity by both enhancing and limiting immune responses
(20). The CD4
+ T-cells are divided into two classes on the
basis of the range of cytokines produced. Th1 cells produce
IL-2 and IFN- , and control the production of IgG2a, where-
as Th2 cells produce IL-4, IL-5, and IL-10, and control the
production of IgG1 and IgE. Because of these interleukin
secretion patterns, Th1 cells promote cell-mediated immu-
nity. In contrast, Th2 cells induce B-cell differentiation and
inhibit cell-mediated immunity and antitumor responses.
In the present study, we found that IFN- mRNA expres-
sion in TG/LLC-injected mice was significantly higher than
that in LLC-injected mice and significantly lower than that
in TG-injected mice. These results indicate that Th1 immune
responses were depressed in Lewis lung carcinoma, and show
that the production of cytokines such as IFN- , TNF- , IL-
12, and IL-2 can arrest proliferation of malignant cells and
prevent the angiogenesis necessary for tumor growth (3, 5,
17, 21, 22). Similar results were reported in melanoma, liver
cancer, and thyroid cancer (22-24). And these phenomena
were also confirmed in the titrations of the IgG subclasses.
The IgG2a titer, which is the primary indicator of a Th1
immune response (25), was significantly increased in the
TG/LLC- and TG/LLC/QA-injected mice four weeks after
infection, while the IgG1 titer, an indicator of the Th2 im-
mune response, remained unchanged.
The development of a vascular supply is essential for the
growth, maturation, and maintenance of normal tissues. It
is also required for wound healing and rapid growth of solid
tumors, and is involved in various other pathologic condi-
tions. Tumor angiogenesis is regulated by the production of
angiogenic stimulators, including members of the fibrob-
last growth factor and the vascular endothelial growth fac-
tor families (13, 14, 26, 27). In the present study, a combi-
nation of bFGF and heparin recruited vessels from the sur-
rounding tissues into the Matrigel. The Hb concentrations
in T. gondii-infected TG-, TG/QA-, TG/LLC-, and TG/LLC/
QA-injected mice were significantly decreased by three- to
four-fold as compared to uninfected QA-, LLC-, and LLC/
QA-injected mice. In a similar study, Hunter et al. (28) show-
ed that T. gondii infection is accompanied by strong systemic
suppression of angiogenesis. This suppression results in severe
hypoxia and avascular necrosis, which are incompatible with
progressive neoplastic growth. Beside this, heyneanol A ob-
tained from an Oriental medicinal herb, sodium pyrogluta-
mate isolated from Agaricus blazei, and glycosaminoglycan
isolated from the African giant snail were also reported as
potent antitumor and anti-angiogenic substances in LLC-
bearing mice (13, 14, 26, 27).
The antitumor activity of cancer immunotherapy has been
explored using advanced molecular and immunological me-
thods. Host immunity is likely related to various factors,
including the route of challenge, mouse strain, antigen prepa-
ration, and adjuvant (29). Our present results suggest that
Toxoplasma infection in LLC-bearing mice induces antitumor
activity against lung cancer through the induction of a Th1-
type immune response and antiangiogenic activity. These
effects were similar or further increased by the modulation
of Quil-A. Quil-A, a saponin derived from the bark of Quil-
laia saponaria Molina, induces antigen presentation, cytokine
production, and T-lymphocyte cytotoxicity (29, 30). How-
ever, the molecular mechanisms underlying Quil-A activity
have not yet been completely described. Infection with T.
gondii leads to the rapid induction of a strong cell-mediated
immune response in the experimental murine host. These
facts suggest the possibility that new immunostimulating
molecules could be found in Toxoplasma organisms.
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